ID
33551
Beschrijving
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02011945
Link
https://clinicaltrials.gov/show/NCT02011945
Trefwoorden
Versies (1)
- 12-12-18 12-12-18 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
12 december 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Chronic Myeloid Leukemia NCT02011945
Eligibility Chronic Myeloid Leukemia NCT02011945
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
Blast Phase CML
Datatype
boolean
Alias
- UMLS CUI [1]
- C0005699
Beschrijving
BCR-ABL Mutation Resistant to Dasatinib | T315I mutation | Other Coding
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0004891
- UMLS CUI [1,2]
- C0026882
- UMLS CUI [1,3]
- C0332325
- UMLS CUI [1,4]
- C1455147
- UMLS CUI [2]
- C3889036
- UMLS CUI [3]
- C3846158
Similar models
Eligibility Chronic Myeloid Leukemia NCT02011945
- StudyEvent: Eligibility
C0023472 (UMLS CUI [2])
C0856536 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
C0023473 (UMLS CUI [1,3])
C0332325 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1704632 (UMLS CUI [3,1])
C2984009 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
C0026882 (UMLS CUI [1,2])
C0332325 (UMLS CUI [1,3])
C1455147 (UMLS CUI [1,4])
C3889036 (UMLS CUI [2])
C3846158 (UMLS CUI [3])